MMP2 and type 2 diabetes mellitus: Evidence from the CECSID trial has shown that miR22-3p downregulation ameliorates visceral adiposity (44) and miR122-5p overexpression affects the extracellular matrix through MMP-2 modulation in Type 2 Diabetes patients (45).